PROGRAMAÇÃO APRESENTAÇÕES ORAIS - SLEP 2019

Horário	21.NOVEMBRO - QUINTA-FEIRA			
	SALÃO CASCAES		TUPI/GUARANI	
10:30-12:00	CÓD.	Apresentação Oral 1 - Diabetes	CÓD.	Apresentação Oral 2 - Neuroendócrino
	OP22	Insulin glargine 300 U/mL (Gla-300) provides effective glycemic control in youths with type 1 diabetes (T1D): the EDITION JUNIOR study	OP26	Probably Pathogenic Variants in New Candidate Genes in Patients with Pituitary Stalk Interruption Syndrome (PSIS) revealed by Whole-Exome Sequencing
	OP24	Variability in basal insulin needs in young patients with type 1 diabetes using continuous subcutaneous insulin infusion and continuous glucose monitoring with predictive low glucose insulin suspension	OP25	An extremely rare novel missense variant p.M304V in SOX3 gene is responsible for an X-linked GH deficiency in a Brazilian patient
	OP23	Longitudinal assessment of Klotho, FGF21, Adiponectin (Adp) and C-reactive-protein (CRP) levels in adolescents and young women with type 1 diabetes (T1D) using contraception.	OP12	Heterozygous GH1 p.R209H variant challenges the assessment of short stature
	OP17	Acquired lipodystrophy among children and adolescents attending a diabetes camp	OP10	Congenital and acquired pituitary insufficiency during the transition stage: first argentine experience in the evaluation of cardiometabolic parameters at the end of GH therapy
	OP16	24-hour glucose profile in healthy adults using a continuous glucose monitoring system.	OP11	Evidence-based approach for current standardized GH, IGF-I and IGFBP-3 assays to rule out GHD in neonates and infants.
	OP21	Follow-up of patientes with type 1 diabetes mellitus who underwent insulin pump training in a pediatric endocrinology center	OP27	Use of Desmopressin for Bilateral Inferior Petrosal Sinus Sampling (BIPSS) in Pediatric Patients with Cushing Disease (CD).
	OP20	Development and validation of an educative manual for adolescents with type 2 diabetes.	OP9	Clinical aspects and common genetics polymorphisms implicated in short stature in sickle cell anemia
15:00-16:00	CÓD.	Apresentação Oral 3 - Metabolismo ósseo	CÓD.	Apresentação Oral 4 - DDS / Gônada
	OP32	Use of anti-FGF23 monoclonal antibody in the treatment of children and adolescents with X-Linked Hypophosphatemic Rickets.	OP44	Safety of chemotherapy for hematologic malignancies as regards testicular endocrine function in children and teenagers
	OP30	Neonatal multiple bone fractures and respiratory distress secondary to congenital hyperparathyroidism	OP40	DHX37: a new player in 46,XY gonadal dysgenesis
	OP29	Hypercalcemia secondary to disseminated BCGitis in a boy with Mendelian Susceptibility to Mycobacteria (MSMD) due to mutation in IFN-? receptor 1 gene (IFNGR1)	OP38	A Novel Anti-Müllerian Hormone (AMH) Gene Mutation in a Patient with Persistent Müllerian Duct Syndrome (PMDS) type 1
	OP28	Etiologies and clinical presentation of persistent hypoparathyroidism (HPT) in 61 children in a single tertiary center	OP37	47,XXY/46,XX chromosomal DSD: challenges in the diagnosis and management
	OP31	Osteogenesis imperfecta type I: which patients should be treated with aminobisphosphonates?	OP39	Characteristics of transgender children and adolescent patients in a pediatric hospital: Multidisciplinary approach
Horário	22.NOVEMBRO - SEXTA-FEIRA			
	SALÃO CASCAES		TUPI/GUARANI	
10:30-12:00	CÓD.	Apresentação Oral 5 - Obesidade e Metabolismo	CÓD.	Apresentação Oral 6 - Crescimento & Puberdade
	OP33	BMI throughout the life-course and its relation with cardiometabolic disorders in early adulthood: results from the Santiago Longitudinal Study	OP14	Response to rhGH Therapy in chilfren with isolated short stature with or without na identified genetic cause
	OP18	BMI trajectory from birth to adulthood and its association with pancreatic ß-CELL function in early adulthood	OP13	Novel familial ACAN gene mutation in a short stature family of an SGA proband
	OP35	Differences between short- and long-term outcomes of laparoscopic sleeve gastrectomy in adolescence.	OP7	Chromosomal IGF1R deletion: array characterization in two patients with structural abnormalities in chromosome 15
	OP15	The overweight and obesity accelerates de skeletal maturity and decrease the growth potential in Mexican children and adolescents.	OP6	Bone age determination in Brazilian children and adolescents: a comparison between computerized BoneXpert, Greulich-Pyle and Tanner-Whitehouse II methods.
	OP36	Nonalcoholic Fatty Liver Disease and morbid obese adolescent submitted to a bariatric surgery.	OP8	Clinical and genetic evaluation of prepubertal children with short stature and advanced bone age
	OP34	Changes on Gut Microbiota After Laparoscopic Sleeve Gastrectomy in Adolescence: Case Reports.	OP42	Evaluation of puberty in patients with Noonan syndrome and mutations in the RAS/MAPK genes.
	OP19	Congenital hyperinsulinemic hypoglucemia, our experience in 34 patients	OP43	Puberty and Growth in Boys with Constitutional Delay of Growth and Puberty
15:00-16:00	CÓD.	Apresentação Oral 7 - Adrenal	CÓD.	Apresentação Oral 8 - Tireoide
	OP4	Validation of serum 17a-hydroxyprogesterone concentration reference ranges by Elisa Method in infants during the first year of life	OP47	Male individuals with Autoimmune Thyroid Disease present higher risk for clustering other Non-Thyroidal Autoimmune Diseases
	OP2	Predictive Cut Off Values of Basal 17-hydroxyprogesterone (17OHP) to Diagnose Non-Classic Congenital Adrenal Hyperplasia due to 21-Hydroxilase Deficiency	OP45	EVALUATION OF PUBLIC CONGENITAL HYPOTHYROIDISM SCREENING PROGRAM IN SOUTHERN BRAZIL AFTER TSH CUTOFF REDUCTION
	OP3	SAMD9 (Sterile Alpha Motif Domain-containing 9) in Adrenocortical Tumors	OP48	The usefulness of free T3 and free T3/free T4 ratio in the differential diagnosis between non-thyroidal illness and central hypothyroidism in pediatric children
	OP1	Clinical presentation and genetic findings in the Paraganglioma Syndrome associated with mutations in SDHB (Pgl4)	OP46	Factors associated with neonatal hyperthyroidism in neonates born to mothers with Graves' disease
	OP41	DSD, bone dysplasia, and the y chromosome?	OP5	Inhibition of IGF1R by IGF-1R/IR inhibitor OSI906 as a targeted therapy for glioblastoma: in vitro & in vivo studies.
Horário	23.NOVEMBRO - SÁBADO			
	SALÃO CASCAES			
10:30-12:00	CÓD.	Apresentação Oral 9 (Finalistas)		
	OPF8	Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia (XLH)		
	OPF6	Sexual dimorphism in the association of BMI trajectory from birth to early adulthood with cardiometabolic risk in adulthood: an approach using dynamic programming		
	OPF7	Validity assessment of the single-point insulin sensitivity estimator (spise) for diagnosis of cardiometabolic risk in 16 years-old male and female adolescents.		
	OPF9	Clinical and Genetic Characterization of a Constitutional Delay of Growth and Puberty Cohort		
	OPF1	Loss-of-function NNT mutations impair antioxidants mechanisms and decreases adrenal steroids secretion in patients with familial glucocorticoid deficieny (FGD)		
	OPF2	MAPK8 activation partially compensates the effects of NNT deficiency in adrenocortical cells		
14:30-15:30	CÓD.	Apresentação Oral 10 (Finalistas)		
	OPF4	Risk alleles of FTO, DRD2 and ANKK1 genes are associated with metabolic risk and have an additive effect on childhood obesity outcome.		
	OPF5	T2DRIVE as a new MRI protocol for the diagnosis of Pituitary stalk interruption syndrome (PSIS).		
	OPF10	Predictive Factors, Clinical Characteristics, Reproductive hormones and Growth Factors During Pubertal Transition in Girls with Transient Thelarche		
	OPF3	Clinical and genetic aspects of pediatric pheochromocytomas and paragangliomas		